Cyted

Cyted, Ltd. is an early cancer diagnostics company. Cyted’s innovative diagnostic platform combines non-invasive tests with data-driven biomarkers for the early detection and risk stratification of cancer and inflammatory diseases. Founded just three years ago, the company has already delivered over 15,000 tests across more than 80 locations in the UK to diagnose and monitor patients with Barrett’s esophagus, a precursor to esophageal cancer. Established by a team including Professor Rebecca Fitzgerald OBE and Dr. Marcel Gehrung from the University of Cambridge, Cyted exemplifies the translation of groundbreaking science into industry.